Nav: Home

AMNOG as a learning system: New study on ingenol mebutate in AK shows added benefit

December 06, 2018

Already in 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether ingenol mebutate offers greater benefit than the appropriate comparator therapy (ACT) for patients with actinic keratosis. With the drug manufacturer presenting no suitable study data at that time, the conclusion was "added benefit not proven". Due to new scientific findings, the manufacturer now applied for a new assessment.

In a randomized controlled trial, ingenol mebutate was now compared directly with the ACT diclofenac/hyaluronic acid. The study showed advantages in one outcome, i.e. complete clearance of visible skin lesions. It remains unclear whether this effect is permanent, however, as the study was ended after 120 days. Regarding other outcomes, there were no statistically significant effects, or no data were available. In particular, it remained unclear whether the treatment prevents squamous cell carcinoma, which can develop from actinic keratosis. Overall, this resulted in a hint of a non-quantifiable, at most considerable, added benefit of ingenol mebutate versus diclofenac/hyaluronic acid.

Good studies are useful even after approval

"Five years ago, the manufacturer presented nothing to show an added benefit of its drug," says Stefan Lange, Deputy Director of IQWiG. "There simply was no study comparing the substance, which was new at the time, with the ACT." According to Stefan Lange, the newly submitted data from a study conducted in the meantime have changed this situation. "Good data are required not only for the approval. Also afterwards, randomized controlled trials can generate the knowledge we need for an early benefit assessment. And this pays off - for patients as well as for the manufacturers," he adds.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.
-end-


Institute for Quality and Efficiency in Health Care

Related Data Articles:

Discrimination, lack of diversity, & societal risks of data mining highlighted in big data
A special issue of Big Data presents a series of insightful articles that focus on Big Data and Social and Technical Trade-Offs.
Journal AAS publishes first data description paper: Data collection and sharing
AAS published its first data description paper on June 8, 2017.
73 percent of academics say access to research data helps them in their work; 34 percent do not publish their data
Combining results from bibliometric analyses, a global sample of researcher opinions and case-study interviews, a new report reveals that although the benefits of open research data are well known, in practice, confusion remains within the researcher community around when and how to share research data.
Designing new materials from 'small' data
A Northwestern and Los Alamos team developed a novel workflow combining machine learning and density functional theory calculations to create design guidelines for new materials that exhibit useful electronic properties, such as ferroelectricity and piezoelectricity.
Big data for the universe
Astronomers at Lomonosov Moscow State University in cooperation with their French colleagues and with the help of citizen scientists have released 'The Reference Catalog of galaxy SEDs,' which contains value-added information about 800,000 galaxies.
What to do with the data?
Rapid advances in computing constantly translate into new technologies in our everyday lives.
Why keep the raw data?
The increasingly popular subject of raw diffraction data deposition is examined in a Topical Review in IUCrJ.
Infrastructure data for everyone
How much electricity flows through the grid? When and where?
Finding patterns in corrupted data
A new 'robust' statistical method from MIT enables efficient model fitting with corrupted, high-dimensional data.
Big data for little creatures
A multi-disciplinary team of researchers at UC Riverside has received $3 million from the National Science Foundation Research Traineeship program to prepare the next generation of scientists and engineers who will learn how to exploit the power of big data to understand insects.

Related Data Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...